Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company`s appeal of the U.S. District Court for the District of New Jersey`s decision that previously granted a preliminary injunction delaying the Company`s launch of LEQSELVI� (deuruxolitinib) in the United States.Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately.While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect.The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI�. The Company will disclose LEQSELVI� launch plans in due course of time.Powered by Capital Market - Live News

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name �FEXUCLUE��. FEXUCLUE�, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE�(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.Powered by Capital Market - Live News

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Powered by Capital Market - Live News

Sun Pharmaceutical Industries and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) (Checkpoint) today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT� (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement.The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint`s closing share price on 07 March 2025, the last trading day prior to today`s announcement.The transaction is expected to be completed in the second calendar quarter of 2025. The transaction is subject to customary closing conditions, including required regulatory approvals and approval by the holders of a majority of the voting power of outstanding shares of Checkpoint common stock, and by the holders of a majority of the shares of Checkpoint common stock that are not held by Fortress or by certain other affiliates of Checkpoint. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. The R&D expense for the nine-month period was $19.3 million. As of September 30, 2024, Checkpoint had a cash balance of $4.7 million, outstanding accounts payable and accrued expenses of $15.6 million, and outstanding accounts payable and accrued expenses -related party of $2.0 million.In connection with the transaction, Fortress, which holds a majority of Checkpoint`s outstanding voting power, has agreed to vote in favor of the transaction.Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that it has been included in the S&P Global Sustainability Yearbook 2025. Sun Pharma has qualified in the Top 5% of pharmaceutical companies assessed by S&P globally for this Yearbook. Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability. This recognition attests to Sun Pharma`s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses.Powered by Capital Market - Live News